This study evaluates advanced magnetic resonance imaging (MRI) methods for adapting radiation therapy for patients with newly diagnosed high grade glioma (HGG). Treatment of newly diagnosed HGG includes surgical removal of tumor, radiation therapy, and chemotherapy with the drug temozolomide. Despite these aggressive measures, nearly all cases come back (recur), and recurrences are typically within the area where radiation therapy was delivered. This study will allow researchers to compare adaptive radiation therapy plans based on changes when using advanced MRI methods to standard of care, non-adaptive plans.
Additional locations may be listed on ClinicalTrials.gov for NCT06108206.
Locations matching your search criteria
United States
New York
New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterStatus: Active
Contact: Tony J. C. Wang
Phone: 212-305-9097
PRIMARY OBJECTIVES:
I. To compare the accuracy and volume of the current standard of care volume definition with an MRI-based adaptive plan in predicting the location of disease progression in patients with high-grade glioma.
II. Assess the prognostic and predictive value of highly-diffusion weighted and perfusion-weighted imaging in estimating progression-free and overall survival in patients with high-grade glioma.
OUTLINE: This is an observational study.
Patients undergo an MRI and receive gadobutrol intravenously (IV) on study. Patients also undergo SOC computed tomography (CT) and receive SOC temozolomide (TMZ) IV on study.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
Principal InvestigatorTony J. C. Wang
